Across TCGA pan-cancer cohorts, SIGLEC31P RNA differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of SIGLEC31P’s most consistent transcriptional readouts.
The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where SIGLEC31P RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SIGLEC31P is over-expressed in tumor.
KIRP are the cancer types where SIGLEC31P tumor–normal differential expression is most reproducible.